New Global Initiative Introduced By Novo Nordisk To Prevent Childhood Obesity In Urban Communities
Novo Nordisk launches a global initiative to combat childhood obesity in urban areas, focusing on disadvantaged communities.

.webp&w=1920&q=75&dpl=dpl_6ysJ9LfPjjK65PGFB6RKfCshR8pW)
Novo Nordisk has launched a global initiative to overcome childhood obesity. The Childhood Obesity Prevention Initiative focuses on disadvantaged urban communities worldwide. This initiative aims to work with city governments, academic institutions, and non-profit organisations to design, implement, and evaluate tailored interventions that promote physical activity and healthy/clean eating in six selected cities.
The initiative is built on a solid, evidence-based framework to evaluate the impact of these interventions. Key metrics such as health-related quality of life, changes in behaviour, and body mass index (BMI) will be tracked in children aged 6-13, with baseline data and follow-ups conducted one and two years after the interventions. The study will utilize a controlled design, comparing a target group receiving the intervention with a control group in each city, aiming to gather data from about 1,000 children per group.
Katrine DiBona, Global Head of Sustainability & Public Affairs at Novo Nordisk, said in a statement, “Childhood obesity is rising at alarming rates all over the world, putting the health and well-being of this and future generations at risk. With a focus on disadvantaged urban communities, the Childhood Obesity Prevention Initiative will provide important evidence and a unique data-led framework to support city leaders in preventing childhood obesity.”
With more than a decade of experience in city-based prevention programs, this initiative will be first launched in six cities across Spain, France, Canada, Brazil, South Africa and Japan.

Simantini Singh Deo works on the latest and trending news happening daily in the pharma world.
More from Pharma News
All stories →
CPHI Milan Pharma Awards 2026 Finalists Announced

Pharming Group Gains FDA Approval for Leniolisib in Children Aged 4–11 with APDS

Discussion